Poor
Not Aligned
Patient Risk:
Moderate
Summary
Multiple substantive claims (indication, incidence percentages, monitoring/screening intervals, urgency directives, contraindications, and black-box warning status) are marked 'absent from the label' in the provided label-adhesion determinations, indicating poor alignment with the supplied FDA label excerpts.
Category Scores
Accurate Statements
Pseudotumor cerebri symptoms with Genotropin can include severe headaches, vision changes, or nausea.
Partially supported by Warnings and Precautions (5.5) which lists headache and visual changes and nausea/vomiting.
Scoliosis risk rises in children with rapid height gains during Genotropin treatment.
Partially supported by Warnings and Precautions (5.11): progression can occur in patients who experience rapid growth; somatropin increases growth rate and should monitor progression.
Somatropin increases the risk of type 2 diabetes due to insulin resistance effects.
Partially supported by Warnings and Precautions (5.4): decrease insulin sensitivity, impaired glucose tolerance/unmasked diabetes mellitus, and new-onset Type 2 diabetes mellitus reported.
The type 2 diabetes risk from somatropin is higher in children predisposed to diabetes.
Partially supported by Warnings and Precautions (5.4): glucose monitoring especially in those with risk factors such as obesity, Turner syndrome, and family history.
Blood glucose should be monitored regularly during somatropin (Genotropin) treatment.
Partially supported by Warnings and Precautions (5.4): glucose levels should be monitored periodically in all patients, especially those with risk factors.
Unsupported Statements
Genotropin (somatropin) is used to treat growth failure in children.
Marked absent from the label in the provided determinations; the supplied label snippets do not include Indications and Usage text.
Genotropin can cause injection-site reactions (pain, redness, or swelling) in up to 30-50% of pediatric patients during early treatment.
Marked absent from the label in provided determinations; injection-site reactions and the specific 30–50% figure are not supported by the supplied excerpts.
Headaches occur in about 15-20% of pediatric patients treated with Genotropin.
Marked absent from the label in provided determinations; incidence percentage not supported by supplied excerpts.
Headaches associated with Genotropin are often mild and resolve over time.
Marked absent from the label in provided determinations; mildness/progression timeframe not supported by supplied excerpts.
Joint or muscle pain affects 10-15% of pediatric patients treated with Genotropin.
Marked absent from the label in provided determinations; incidence percentage not supported by supplied excerpts.
Joint or muscle pain with Genotropin is linked to rapid growth spurt effects.
Marked absent from the label in provided determinations; supplied excerpts do not link arthralgia/myalgia to 'rapid growth spurt effects' for this symptom.
Increased intracranial pressure (pseudotumor cerebri) happens in 1-5% of children treated with Genotropin.
Marked absent from the label in provided determinations; no incidence range is provided in the supplied excerpt.
Pseudotumor cerebri associated with Genotropin requires immediate medical attention to avoid permanent vision loss.
Marked absent from the label in provided determinations; urgency/"avoid permanent vision loss" wording not supported by supplied excerpts.
Scoliosis risk rises in children with rapid height gains during Genotropin treatment.
Partially supported (5.11) for risk/progression concept, but the claim set includes additional elements elsewhere (e.g., screening interval) that are unsupported; however this specific statement is marked partially supported in determinations and therefore not categorized as fully unsupported here.
Screening for scoliosis is recommended every 3-6 months in children receiving growth hormone due to rapid height gains.
Marked absent from the label in provided determinations; specific interval not stated in supplied excerpt.
Slipped capital femoral epiphysis occurs in under 1% of children treated with Genotropin.
Marked absent from the label in provided determinations; no incidence threshold is provided in supplied excerpt.
Slipped capital femoral epiphysis associated with Genotropin demands urgent orthopedic care.
Marked absent from the label in provided determinations; excerpt advises evaluation and management accordingly but does not use 'urgent orthopedic care' directive.
Genotropin is contraindicated in active cancer.
Marked absent from the label in provided determinations; contraindication language for 'active cancer' is not shown in supplied excerpts.
Genotropin is debated for use in patients with a history of cancer.
Marked absent from the label in provided determinations; supplied excerpt discusses neoplasm risk/monitoring rather than 'debated' use.
Long-term studies show no clear increased relapse in non-cancer growth disorders with Genotropin.
Marked absent from the label in provided determinations; supplied excerpt does not support this statement.
A 2002 FDA analysis of over 18,000 children found 11 deaths from leukemia versus 4.3 expected.
Marked absent from the label in provided determinations; no such analysis data are present in supplied excerpts.
Causality for leukemia deaths in the 2002 FDA analysis is unproven.
Marked absent from the label in provided determinations; no causality discussion or that specific analysis is present in supplied excerpts.
The risk of leukemia deaths from the 2002 FDA analysis appears low, about 1 in 5,000.
Marked absent from the label in provided determinations; no such calculated risk is present in supplied excerpts.
No broad cancer signal was found in post-marketing data for Genotropin.
Marked absent from the label in provided determinations; not present in supplied excerpts.
Over-rapid growth with Genotropin can cause orthopedic problems including Legg-Calve-Perthes disease.
Marked absent from the label in provided determinations; supplied excerpt discusses slipped capital femoral epiphysis and osteonecrosis, not Legg-Calve-Perthes specifically.
Thyroid tests are needed at the start of Genotropin therapy.
Marked absent from the label in provided determinations; supplied excerpt says patients should have periodic thyroid function tests, not explicitly 'at the start.'
Thyroid tests are needed yearly during Genotropin therapy.
Marked absent from the label in provided determinations; specific 'yearly' interval not supported by supplied excerpt.
Fluid retention with Genotropin can lead to edema in 5-10% of children.
Marked absent from the label in provided determinations; supplied excerpt does not provide a pediatric edema incidence range.
Genotropin is contraindicated in acute critical illness.
Marked absent from the label in provided determinations; supplied excerpt describes increased mortality in acute critical illness and notes weighing benefit, but the claim 'contraindicated' is not supported by the provided contraindication excerpt text.
Genotropin is contraindicated in closed epiphyses.
Marked absent from the label in provided determinations; closed epiphyses contraindication text is not included in supplied excerpts.
Use of Genotropin in Prader-Willi syndrome carries caution due to increased choking/aspiration risk.
Marked absent from the label in provided determinations; supplied excerpt focuses on upper airway obstruction/sleep apnea and respiratory infections, not 'choking/aspiration.'
Prader-Willi syndrome use of Genotropin is associated with 1-2% mortality from respiratory issues.
Marked absent from the label in provided determinations; supplied excerpt reports fatalities but provides no mortality percentage.
Genotropin has a black-box warning for increased mortality in critically ill children.
Marked absent from the label in provided determinations; provided excerpts do not show any boxed/black-box warning formatting.
Contradictions
Low
AI Statement
Genotropin is contraindicated in active cancer.
Label Reference
4 Contraindications (not provided in supplied excerpt text); provided determinations mark this as absent from label rather than supported.
Low
AI Statement
Genotropin is contraindicated in acute critical illness.
Label Reference
5.1 Acute Critical Illness describes increased mortality and weighing benefit vs risk; contraindication wording not supported in supplied excerpt.
Important Omissions
For pediatric use and safety claims, the response should align with label-described monitoring/management actions (e.g., fundoscopy before and periodically during therapy; stop treatment if papilledema observed; interrupt treatment for Prader-Willi upper airway obstruction/sleep apnea signs).
Importance:
Moderate
For diabetes/glucose monitoring claims, the label also states that doses of antihyperglycemic medications may require adjustment—this was not mentioned.
Importance:
Moderate
For acute critical illness, label states safety of continuing replacement doses is not established and benefit should be weighed against risk—this balancing concept was not captured with on-label phrasing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several high-stakes safety-related claims are unsupported by supplied label excerpts (black-box status, contraindication status, numeric incidence rates, and urgency/screening intervals). While these are not verified as false using external data, the misalignment could misinform clinical expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Numerous safety and dosing/management-related assertions are marked absent from the provided FDA label excerpts (including numeric rates, urgency, screening intervals, contraindication and black-box warning status).
Suggested Improvement
Restrict statements to the exact label-supported content in the provided sections (5.1, 5.2, 5.4, 5.5, 5.7, 5.9, 5.10, 5.11, and 4/2 where text is available). Remove unsupported incidence percentages, avoid claiming specific intervals or boxed warning status unless explicitly shown, and use label phrasing for monitoring actions and risk-benefit considerations.